List of Contributors:

Prof. Abdulrahman Jazieh, MD, MPH
Chairman of Saudi Lung Cancer Association, Lung Cancer Guidelines Committee
Prof. Khalid Kattan, Al Faisal University, Riyadh
Dr. Nagwa Ibrahim, Prince Sultan Military Medical City, Riyadh
Dr. Abdullah Al Twairqi, King Fahad Medical City, Riyadh
Dr. Turki Al Fayae, Princess Noorah Oncology Center, Jeddah
Dr. Khalid Al Saleh, King Khalid University Hospital, Riyadh
Dr. Hamad Husseini, King Faisal Specialist Hospital and Research Center, Riyadh
Dr. Ahmed Bamousa, Prince Sultan Military Medical City, Riyadh
Dr. Ameen Al Omair, King Faisal Specialist Hospital and Research Center, Riyadh
Dr. Adnan Hebshi, King Faisal Specialist Hospital and Research Center, Jeddah
Dr. Saif Al Thaqafi, King Abdulaziz Medical City, Riyadh
Dr. Sarah Al Ghanaam, King Abdulaziz Medical City, Riyadh
Dr. Shurki Loutfi, King Abdulaziz Medical City, Riyadh
Dr. Azzam Khankan, King Abdulaziz Medical City, Riyadh
RN. Mohammad Omar Al Kaiyat, (CCRP) King Abdulaziz Medical City (Project coordinator)
For interactive lung cancer guideline and point of care resources click below:

- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer

TABLE OF CONTENTS:

- Evidence Levels ................................................................. 4
- All Lung Cancer Patients ....................................................... 4
  - Initial Assessment Plan ...................................................... 4
  - Diagnosis ........................................................................ 4
  - Staging ........................................................................... 5
  - General ........................................................................... 5
- Non-Small Cell Lung Cancer .................................................. 6
  - Clinical Stage IA .............................................................. 6
  - Clinical Stage IB .............................................................. 6
  - Clinical Stage IIA ............................................................. 7
  - Clinical Stage IIB ............................................................. 7
  - Clinical Stage IIIA ............................................................ 8
  - Clinical Stage IIIB and Unresectable IIIA ......................... 9
  - Stage IV ........................................................................ 9
  - Follow-up of Non-Small Cell Lung Cancer .................... 16
- Small Cell Lung Cancer ........................................................ 18
  - Stage I-IIIA ..................................................................... 18
  - Stage IV ........................................................................ 18
  - Follow-up and Surveillance ............................................. 18
- Appendix
  - Metastatic NSCLC Management Guidelines .................. 19
The following evidence levels (EL) were adopted for these guidelines:

- **(EL-1) High Level**: well conducted phase III randomized studies or well done meta-analyses.
- **(EL-2) Intermediate Level**: good phase II data or phase III trials with limitations.
- **(EL-3) Low Level**: observational or retrospective studies, expert opinions.

### General Oncology Recourses

**I. ALL LUNG CANCER PATIENTS**

**General Lung Cancer Recourses**

1.1 **INITIAL PATIENT ASSESSMENT.**

1.1.1 Perform history and physical examination, and document smoking history and performance status.

1.1.2 Perform the following laboratory tests: Complete blood count (CBC), differential, liver function test (LFT), renal function, electrolytes, calcium, serum albumin, magnesium and phosphorus.

1.1.3 Two-view chest x-ray.
1.2 DIAGNOSIS

1.2.1 Observe adequate tissue specimen for diagnostic and predictive markers.

1.2.2 Confirm histopathological diagnosis of lung cancer and determine the histological subtypes of non-small cell lung cancer i.e. adenocarcinoma vs squamous cell vs large cell carcinoma using most recent pathological classification of lung cancer. Utilization of proper immunohistochemistry is try staining (minimum panel to include TTF1 (most important), CK7, and CK20 for adenocarcinoma and P40 (preferred) or P63 to minimize the diagnosis of “not otherwise specified” (NOS).

1.2.3 Obtain epidermal growth factor receptor (EGFR) mutation testing by PCR in certified laboratory for all histology except pure squamous cell.

1.2.4 In EGFR Wild Type (WT) tumors, obtain EML4-ALK fusion test by FISH in certified laboratory. IHC can be done to screen for positive tumors to be tested by FISH.

1.2.5 For patients with wild type EGFR & ALK, consider obtaining the ROS1 test.

1.2.6 If immune therapy is considered, PDL1 testing by IHC can be done.

1.3 STAGING

1.3.1. Non-Small Cell Lung Cancer

1.3.1.1 Obtain contrast enhanced CT scan of the chest and upper abdomen.

1.3.1.2 Obtain Magnetic Resonance Imaging (MRI) of brain for stages IB-IV (preferred over contrast enhanced CT scan).

1.3.1.3 Obtain total body positron emission tomography/computed tomography (PET/CT) scan when available if the patient is considered for radical therapy (such as surgery or chemoradiotherapy).

1.3.1.4 Obtain bone scan for stages IB-IV if PET/CT is not done.

1.3.1.5 Perform mediastinoscopy in selected cases; i.e. clinical stages (IB-III). Mediastinoscopy can be omitted if PET/CT scan is negative.

1.3.1.6 Determine precise TNM staging using 7th edition (2009).

1.3.2. Small Cell Lung Cancer

1.3.2.1 Obtain contrast enhanced CT scan of chest and upper abdomen.

1.3.2.2 Obtain Magnetic Resonance Imaging (MRI) of brain for stages IB-IV (preferred over contrast enhanced CT scan which can be if MRI is not available).

1.3.2.3 Obtain PET/CT scan if the disease in stages I-III.

1.3.2.4 Obtain bone scan if PET/CT is not done.

1.3.2.5 Determine precise TNM staging using 7th edition (2009).
1.4 PRE-TREATMENT ASSESSMENT

1.4.1 Discuss all new cases in a multidisciplinary conference (Tumor Board).

1.4.2 Obtain cardiopulmonary assessment (Pulmonary Function test, 6 minute walk, ECG and echo) if surgery considered and PFT for curative radiotherapy is considered.

1.5 GENERAL

1.5.1 Offer available clinical research studies.

1.5.2 Counsel about smoking cessation and pulmonary rehabilitation.

II. NON-SMALL CELL LUNG CANCER

2.1 CLINICAL STAGE IA

2.1.1 Anatomical surgical resection and mediastinal lymph node sampling.

2.1.2 No need for adjuvant chemotherapy (EL-1).

2.1.3 If optimal surgery cannot be performed, consider limited surgery (wedge resection or segmentectomy) or SBRT.

2.1.4 For positive surgical margins perform re-resection (EL-1). If not possible offer curative radiotherapy (EL-2).

2.1.5 If surgical resection is not possible, offer curative radiotherapy.

2.1.6 Follow up and surveillance per section 2.8 (follow up of non-small cell lung cancer).

2.2 CLINICAL STAGE IB

2.2.1 Anatomical surgical resection mediastinal lymph node sampling... (EL-1) or dissection (EL-3).

2.2.2 For lesions ≥ 4 cm or high-risk features (poorly differentiated, wedge resection, minimal margins, vascular Invasion), consider adjuvant chemotherapy. (EL-2).

2.2.3 Chemotherapy of choice: 4-6 cycles of cisplatin (carboplatin only if cisplatin is contraindicated) with docetaxel, gemcitabine or venorelbine (EL-1) or carboplatin and paclitaxel.

2.2.4 If optimal surgery cannot be performed, consider limited surgery (wedge resection or segmentectomy) (EL-1).

2.2.5 For positive surgical margins perform re-resection (EL-1) and if not possible, offer curative radiotherapy (EL-2).

2.2.6 If surgical resection is not possible, offer curative radiotherapy.

2.2.7 Follow up and surveillance per section 2.8 (follow up of non-small cell lung cancer).

2.3 CLINICAL STAGE IIA

2.3.1 Anatomical surgical resection with lobectomy or pneumonectomy and me
2.3.2 Offer adjuvant chemotherapy as per 2.2.3 (EL-1).

2.3.3 If optimal surgery cannot be performed, consider limited surgery (wedge resection or segmentectomy) or SBRT.

2.3.4 For positive surgical margins perform re-resection (EL-1) and if not possible, offer curative radiotherapy (EL-2).

2.3.5 If surgical resection is not possible, offer curative radiotherapy.

2.3.6 Follow up and surveillance per section 2.8 (follow up of non-small cell lung cancer).

2.4 CLINICAL STAGE IIB

2.4.1 Anatomical surgical resection and mediastinal lymph node sampling (EL-1) or dissection (EL-3).

2.4.2 Offer adjuvant chemotherapy. Similar to 2.2.3 (EL-1).

2.4.3 Superior sulcus tumors patients should be induced by cisplatin/etoposide with concurrent radiation therapy followed by surgical resection (EL-2) and 2 cycles of adjuvant chemotherapy. Assess disease extent by using MRI at baseline and pre-operative.

2.4.4 For T3 N0 M0 perform en-bloc resection (EL-1).

2.4.5 If optimal surgery cannot be performed, consider limited surgery (wedge resection or segmentectomy) (EL-1).

2.4.6 For positive surgical margins perform re-resection (EL-1) and if not possible, offer curative radiotherapy (EL-2).

2.4.7 If surgical resection is not possible, offer curative radiotherapy.

2.4.8 Follow up and surveillance per section 2.8 (follow up of non-small cell lung cancer).

2.5 CLINICAL STAGE IIIA

2.5.1 For T3 N1 M0 perform en-bloc resection (EL-1).

2.5.2 For superior sulcus tumor, offer treatment similar to 2.4.3 (EL-2).

2.5.3 For N2 disease offer neoadjuvant concurrent chemoradiotherapy (EL-1) assess response. If resectable, offer surgery. For non-resectable tumors, continue with the appropriate treatment based on disease status.

2.5.4 If positive N2 disease discovered during surgery by frozen section abort surgery if pneumonectomy is required (EL-2).

2.5.5 Incidental pathological N2 disease, adjuvant chemotherapy. is indicated (EL-1) radiotherapy can be considered (EL-3).

2.5.6 For T4 (2 nodules in ipsilateral separate lobes), offer pneumonectomy followed by adjuvant chemotherapy.
2.5.7 T4 (mediastinal involvement or main airway involvement), offer surgery if potentially curative, if not possible, offer definitive concurrent chemo- radiotherapy (2.5.1.)

2.5.8 For non N2 stage IIIA, not specified above, offer surgical resection with Adjuvant chemotherapy (EL- 1). Adjuvant chemotherapy for positive margins.

2.5.9 Follow up and surveillance per section 2.8 (follow up of non-small cell lung cancer).

2.6 CLINICAL STAGE IIIB AND UNRESECTABLE IIIA

2.6.1 Offer concurrent chemo- radiotherapy (EL1) followed by chemotherapy (EL2). Surgical resection for selected cases could be offered.

2.6.2 Follow up and surveillance per section 2.8 (follow up of non-small cell lung cancer).

2.7 STAGE IV

* Obtain Palliative care. consultation / evaluation.

2.7.1 Systemic Therapy (See Table)

2.7.1.1 Stage M1a (with pleural effusion) assess the need for thoracentesis and pleurodesis. Offer systemic therapy as below.

2.7.1.2 With brain metastases

• Consider surgery for patient with single brain metastasis.

• Refer to radiation oncology for local treatment of the CNS disease.

• After CNS disease control, start systemic therapy as in 2.7.1.4.

2.7.1.3 Isolated adrenal metastasis. Consider surgical resection (confirm histologically before surgery). Discuss with multidisciplinary team.

2.7.1.4 No brain metastases/Treated brain disease, no prior systemic treatment for metastatic disease. (See Table 1)

2.7.1.4.1 Adenocarcinoma/non-squamous EGFR mutation (excluding exon 20 mutations or primary resistant mutations)

A. First line:

1. Performance Status 0-2:
   - Use TKIs (Erlotinib, Gefitinib, or Afatinib) (EL1).
   - Systemic chemotherapy (platinum doublet +/- bevacizumab) (Pemetrexed is preferred over gemcitabine).

2. Performance Status 3:
   - Use TKIs (Erlotinib, Gefitinib, or Afatinib).
   - Single agent chemotherapy (Pemetrexed is preferred over gemcitabine)

2. Performance Status 4:
   - Use TKIs (Erlotinib, Gefitinib, or Afatinib).
B. Maintenance:

1. Performance Status 0-2:
   - Continuation or switch maintenance with TKIs (EL1). If was not started on TKIs, patient should be switched to TKIs as soon as possible
   - Continue Bevacizumab, if started in first line.

2. Performance Status 3 and 4:
   - Continuation or switch maintenance with TKIs. If was not started on TKIs, patient should be switched to TKI as soon as possible.

C. Second line

   * Consider re-biopsy to assess the cause of resistance if TKI is used in first line

1. Performance Status 0-2:
   - Use TKIs, if not used in first line.
   - Systemic Chemotherapy (platinum doublet+/bevacizumab) (Pemetrexed is preferred over gemcitabine).
   - Consider using Ramucirumab

2. Performance Status 3:
   - Use TKIs, if not used in first line.
   - If TKI used, consider single agent chemotherapy (Pemetrexed preferred over gemcitabine)

3. Performance Status 4:
   - Use TKIs, if not used in first line.
   - If TKIs were used, refer to Palliative care.

D. Third Line and Beyond

1. Performance Status 0-2:
   - Use TKIs, if not used before.
   - Consider immunotherapy (Nivolumab or Pembrolizumab)
   - Systemic chemotherapy (single agent chemotherapy, Pemetrexed if not used, docetaxel, etc).

2. Performance Status 3 and 4:
   - Use TKIs, if not used in first line.
   - If TKIs were used, refer to palliative care.

2.7.1.4.2. ALK positive Adenocarcinoma/non-squamous

A. First line:

1. Performance Status 0-2:
   - Use Crizotinib. (EL1).
   - Systemic Chemotherapy (platinum doublet+/bevacizumab) (Pemetrexed is preferred over gemcitabine).

2. Performance Status 3:
   - Use Crizotinib.
   - Single agent chemotherapy (Pemetrexed preferred over gemcitabine).

2. Performance Status 4:
   - Use Crizotinib.
   - Palliative care.
B. Maintenance:

1. Performance Status 0-2:
   - Continuation or switch maintenance with Crizotinib. If was not started on Crizotinib, patient should be switched to Crizotinib as soon as possible.
   - Continue Bevacizumab, if started in first line.

2. Performance Status 3 and 4:
   - Continuation or switch maintenance with Crizotinib. If was not started on Crizotinib, patient should be switched to Crizotinib as soon as possible.

C. Second line
   * Consider re-biopsy to assess the cause of resistance if TKI is used n first line

1. Performance Status 0-2:
   - Use Ceritinib, if Crizotinib used before.
   - Use Crizotinib, if not used in first line.
   - Systemic Chemotherapy (platinum doublet+/- bevacizumab) (Pemetrexed is preferred over gemcitabine).
   - Consider using Ramucirumab
   - Consider using Nivolumab or pembrolizumab

2. Performance Status 3 and 4:
   - Use Ceritinib, if Crizotinib used before
   - Use Crizotinib, if not used before.

D. Third Line and Beyond

1. Performance Status 0-2:
   - Use Crizotinib or Ceritinib, if not used before.
   - Systemic Chemotherapy (single agent chemotherapy, Pemetrexed, if not used, docetaxel, etc)
   - Consider immunotherapy (Nivolumab and Pembrolizumab)

2. Performance Status 3 and 4:
   - Use Crizotinib, if not used in first line.
   - If both agent is used, Palliative care..

2.7.1.4.3. EGFR/ALK wild type Adenocarcinoma/non-squamous (Including EGFR Exon 20 mutation or primary resistance mutation)

A. First line:

1. Performance Status 0-2:
   - Systemic Chemotherapy (platinum doublet+/-bevacizumab) (Pemetrexed is preferred over gemcitabine).

2. Performance Status 3:
   - Single agent chemotherapy (Pemetrexed is preferred over gemcitabine).
   - Palliative care.

3. Performance Status 4:
   - Palliative care.
B. Maintenance:

1. Performance Status 0-2:
   - Continue or switch maintenance with Pemetrexed.
   - Continue Bevacizumab, if started in first line.

2. Performance Status 3:
   - Continue or switch maintenance with Pemetrexed.

3. Performance Status 4:
   - Palliative care.

C. Second line

1. Performance Status 0-2:
   - Single Agent Systemic Chemotherapy (Pemetrexed if not used, docetaxel).
   - Consider using Nivolumab or pembrolizumab.
   - Consider using Ramucirumab.

2. Performance Status 3:
   - Single Agent Systemic Chemotherapy (Pemetrexed if not used, docetaxel).
   - Erlotinib (only TKI) can be used. EL3.

3. Performance Status 4:
   - Palliative care.

D. Third Line and Beyond

1. Performance Status 0-2:
   - Single agent systemic therapy.
   - Erlotinib (only TKI) can be used. EL3.

2. Performance Status 3 and 4:
   - Palliative care.

2.7.1.4.4. Adenocarcinoma/non-squamous with (EGFR and ALK unknown status)

A. First line:

1. Performance Status 0-2:
   - Systemic Chemotherapy (platinum doublet+/bevacizumab).
   - Pemetrexed is preferred over gemcitabine.

2. Performance Status 3:
   - Single agent chemotherapy (Pemetrexed is preferred over gemcitabine).
   - Use TKIs (Erlotinib).

3. Performance Status 4:
   - Palliative care.

B. Maintenance:

1. Performance Status 0-2:
   - Continue or switch maintenance with Pemetrexed.
   - Continue Bevacizumab, if started in first line.
2. Performance Status 3:
   - Continue or switch maintenance with Pemetrexed.
3. Performance Status 4:
   - Palliative care.

C. Second line

1. Performance Status 0-2:
   - Single Agent Systemic Chemotherapy (Pemetrexed, if not used, docetaxel).
   - Immune therapy (Nivolumab or pembrolizumab)
   - Erlotinib can be used. EL2.
   - Consider using Ramucirumab
2. Performance Status 3 and 4:
   - Palliative care.

D. Third Line and Beyond

1. Performance Status 0-2:
   - Systemic Chemotherapy (single agent chemotherapy, Pemetrexed if not used, docetaxel).
2. Performance Status 3 and 4:
   - Palliative care.

2.7.1.4.5 Squamous cell carcinoma:

A. First line:

1. Performance Status 0-2:
   - Systemic Chemotherapy (platinum doublet) (No Bevacizumab or Pemetrexed).
2. Performance Status 3:
   - Single agent chemotherapy (No Pemetrexed).
3. Performance Status 4:
   - Palliative care.

B. Maintenance:

1. Performance Status 0-2:
   - Continuation or switch maintenance with docetaxel.
2. Performance Status 3 and 4:
   - Palliative care.

C. Second line

1. Performance Status 0-2:
   - Single agent systemic Chemotherapy (No Pemetrexed).
   - Immune therapy (Nivolumab or pembrolizumab)
   - Consider using Ramucirumab
2. Performance Status 3:
   - Single agent systemic therapy
3. Performance Status 4:
   - Palliative care.

D. Third Line and Beyond

1. Performance Status 0-2:
   - Single agent systemic therapy
   - Consider using Nivolumab or pembrolizumab if it’s not used before
2. Performance Status 3 and 4:
   - Palliative care.
2.8 FOLLOW UP OF NON SMALL CELL LUNG CANCER

Evaluation includes: History and physical examination, laboratory and chest x-ray.

2.8.1 For tumor stage I-III: evaluation every 3 months for 2 years then every 6 months for 3 years then annually. CT scan of the chest every 6 months for 2 years then annually for additional 3 years. Consider annual screening CT scan after 5 years.

2.8.2 Stage IV: evaluation every 2-3 months as clinically indicated.

III. SMALL CELL LUNG CANCER

3.1 Stage I-III (Previously called limited stage):

3.1.1 Offer cisplatin/ etoposide with radiation therapy then consolidate with two cycles of cisplatin/ etoposide (EL-1). May substitute cisplatin with carboplatin in patients with neuropathy, renal dysfunction or hearing problem.

3.1.2 After definitive therapy with any response offer prophylactic cranial irradiation (PCI) (EL-1).

3.1.3 For stage (T1-2 N0 confirmed by Mediastinoscopy ), offer surgical resection followed by chemotherapy and prophylactic brain radiotherapy (EL-2).

3.1.4 Follow up and surveillance per section 3.3.

3.2 STAGE IV (Previously Extensive Stage)

3.2.1 Offer cisplatin/ etoposide or cisplatin /irinotecan x 6 cycles (EL-1). Use of carboplatin cisplatin is not indicated.

3.2.2 After definitive chemotherapy with evidence of response and good performance status offer (EL-1). Thoracic irradiation and prophylactic cranial irradiation (PCI).

3.2.3 For previously treated patients who relapsed in less than 6 months from initial treatment, offer topotecan (EL-1) or cyclophosphamide, adriamycin and vincristin (CAV), or camptozar.

3.2.4 For relapse after six months from initial treatment, may use original regimen.

3.2.5 Follow up and surveillance per section 3.3

3.3 FOLLOW UP AND SURVEILLANCE

3.3.1 Evaluation includes: history and physical examination, laboratory data and chest x-ray.

3.3.2 Stage I-III: evaluation every 3 months for 2 years then every 6 months for 3 years then annually. CT scan of the chest every 6 months for 2 years then annually for additional 3 years. Consider annual screening CT scan after 5 years.

3.3.3 Stage IV: evaluation every 2-3 months as clinically indicated.
## Appendix 2. Systematic Therapy Regimens in NSCLC

<table>
<thead>
<tr>
<th>Chemotherapy Regimen</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carboplatin AUC 6 + paclitaxel 225 mg/m² on day 1</td>
<td>Schiller 2002</td>
</tr>
<tr>
<td>21 DAYS cycle for 6 cycles</td>
<td>Strauss 2008</td>
</tr>
<tr>
<td>Cisplatin 75 mg/m² + docetaxel 75 mg/m² on day 1</td>
<td>Strauss 2008</td>
</tr>
<tr>
<td>21 day cycle for 6 cycles</td>
<td>Schiller 2002</td>
</tr>
<tr>
<td>Cisplatin 100 mg/m² + gemcitabine 1000 mg/m² on day 1 &amp; 8, 15</td>
<td>Schiller 2002</td>
</tr>
<tr>
<td>28 day cycle for 6 cycles</td>
<td>Schiller 2002</td>
</tr>
<tr>
<td>Carboplatin AUC 5 + gemcitabine 1000 mg/m² on day 1 &amp; 8, 21 days cycle for 6 cycles</td>
<td>Zatloukal P 2003</td>
</tr>
<tr>
<td>Cisplatin 75 mg/m² + vinorelbine 25 mg/m² on day 1 &amp; 8, 21 days cycle for 6 cycles</td>
<td>Winton 2005</td>
</tr>
<tr>
<td>Gemcitabine 1250 mg/m² (day 1 and 8)</td>
<td>Sederholm 2005</td>
</tr>
<tr>
<td>Docetaxel 75 mg/m² 21 day cycle</td>
<td>Shepherd FA 2000</td>
</tr>
<tr>
<td>Pemetrexed 500 mg/m² 21 day cycle</td>
<td>Hanna N 2004</td>
</tr>
<tr>
<td>Toptecan 1.5 mg/m² (day 1 to 5) 21 day cycle</td>
<td>Ramlau 2006</td>
</tr>
<tr>
<td>Gefitinib 250 mg daily 28 day cycle</td>
<td>Edward 2008</td>
</tr>
<tr>
<td>Erlotinib 150 mg po daily 28 day cycle</td>
<td>Shepherd FA 2005</td>
</tr>
<tr>
<td>Pemetrexed (500 mg/m² IV) 3 week cycle</td>
<td>Giorgio 2009</td>
</tr>
<tr>
<td>Afatinib 40 mg po daily 28 day cycle.</td>
<td>Sequest 2013</td>
</tr>
<tr>
<td>Crizotinib 250 mg po BID 28 day cycle</td>
<td>Sahw 2013</td>
</tr>
<tr>
<td>Ceritinib 750 mg p.o daily 28 day cycle</td>
<td>Shaw 2014</td>
</tr>
<tr>
<td>Nivolumab IV: 3 mg/kg once every 2 weeks until disease progression or unacceptable toxicity</td>
<td>Brahmer 2015</td>
</tr>
<tr>
<td>Pembrolizumab IV: 2 mg/kg once every 3 weeks until disease progression or unacceptable toxicity</td>
<td>Garon2015</td>
</tr>
<tr>
<td>Ramucirumab IV: 10 mg/kg on day 1 every 21 days in combination with docetaxel; continue until disease progression or unacceptable toxicity</td>
<td>Garon 2012</td>
</tr>
</tbody>
</table>

### Metastatic

<table>
<thead>
<tr>
<th>Chemotherapy Regimen</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carboplatin AUC 5 + gemcitabine 1000 mg/m² on day 1 &amp; 8</td>
<td>Zatloukal P 2003</td>
</tr>
<tr>
<td>21 day cycle for 6 cycles</td>
<td></td>
</tr>
<tr>
<td>Cisplatin 75 mg/m² + vinorelbine 25 mg/m² on day 1 &amp; 8</td>
<td>Winton 2005</td>
</tr>
<tr>
<td>Paclitaxel (200 mg/m²) + carboplatin (AUC 6) + bevacizumab (15 mg/kg) every 21 days</td>
<td>Sandler 2006</td>
</tr>
</tbody>
</table>

### Adjuvant

- Carboplatin AUC 6 + paclitaxel 225 mg/m² on day 1 21 DAYS cycle for 6 cycles
- Cisplatin 75 mg/m² + docetaxel 75 mg/m² on day 1 21 day cycle for 6 cycles
- Cisplatin 100 mg/m² + gemcitabine 1000 mg/m² on day 1 & 8, 15 28 day cycle for 6 cycles Usual practice is to omit day 15 and use every 21 days

### Concurrent with Chemoradation

- Carboplatin AUC 2 + Paclitaxel 45 mg/m² Weekly with radiation Socinski 2001
- Cisplatin 50 mg/m² (days 1, 8, 29, 36) + etoposide 50 mg/m² (day 1 to 5 and 29 to 33) Week 1 and 5 Albain 2002

### Metastatic

- Carboplatin AUC 6 + paclitaxel 225 mg/m² on day 1 121 days cycle for 6 cycles Schiller 2002 Strauss 2008
- Cisplatin 75 mg/m² + docetaxel 75 mg/m² on day 121 days cycle for 6 cycles Schiller 2002 Strauss 2008
- Cisplatin 100 mg/m² + gemcitabine 1000 mg/m² on day 1 & 8, 15 28 day cycle for 6 cycles Usual practice is to omit day 15 and use every 21 days Schiller 2002

### Single agent regimens

- Gemcitabine 1250 mg/m² (day 1 and 8) 21 day cycle
- Docetaxel 75 mg/m² 21 day cycle
- Pemetrexed 500 mg/m² 21 day cycle
- Toptecan 1.5 mg/m² (day 1 to 5) 21 day cycle
- Gefitinib 250 mg daily 28 day cycle
- Erlotinib 150 mg po daily 28 day cycle
- Pemetrexed (500 mg/m² IV) 3 week cycle
- Afatinib 40 mg po daily 28 day cycle.
- Crizotinib 250 mg po BID 28 day cycle
- Ceritinib 750 mg p.o daily 28 day cycle
- Nivolumab IV: 3 mg/kg once every 2 weeks until disease progression or unacceptable toxicity
- Pembrolizumab IV: 2 mg/kg once every 3 weeks until disease progression or unacceptable toxicity
- Ramucirumab IV: 10 mg/kg on day 1 every 21 days in combination with docetaxel; continue until disease progression or unacceptable toxicity
### Diagnosis

1. Determining Histology Subtype
2. EGFR Mutation Testing
3. EML4 -ALK-Fusion Testing
4. PDL1 testing

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Performance Status</th>
<th>Non Squamous Cell Carcinoma</th>
<th>Squamous Cell Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EGFR+</td>
<td>EML4-ALK+</td>
<td>EGFR WT</td>
</tr>
<tr>
<td><strong>First line</strong></td>
<td>TKI or Platinum doublet (Pemetrexed) +/-Bevacizumab</td>
<td>Crizotinib or Platinum doublet (Pemetrexed) +/-Bevacizumab</td>
<td>Platinum doublet (Pemetrexed) +/-Bevacizumab</td>
</tr>
<tr>
<td>0-2</td>
<td>TKI single agent chemotherapy</td>
<td>Crizotinib, erlotinib or single agent chemotherapy</td>
<td>Single agent chemotherapy or erlotinib</td>
</tr>
<tr>
<td>3</td>
<td>TKI Palliative Care</td>
<td>Crizotinib* Palliative Care</td>
<td>Palliative Care</td>
</tr>
<tr>
<td>4</td>
<td>TKI Palliative Care</td>
<td>Crizotinib, Pemetrexed Bevacizumab**</td>
<td>Pemetrexed or erlotinib Bevacizumab (CM)</td>
</tr>
<tr>
<td><strong>Maintenance</strong></td>
<td>TKI or Pemetrexed Bevacizumab (CM)</td>
<td>Crizotinib, Pemetrexed Bevacizumab**</td>
<td>Pemetrexed or erlotinib Bevacizumab (CM)</td>
</tr>
<tr>
<td>0-2</td>
<td>IT, TKI if not used, Pemetrexed or docetaxel</td>
<td>Crizotinib, if not used, Ceritinib if Crizotinib is used. TKI, Pemetrexed or docetaxel</td>
<td>IT, Pemetrexed if not used. IT, Ramucirumab+ Docetaxel</td>
</tr>
<tr>
<td><strong>Second Line</strong></td>
<td>TKI, if not used</td>
<td>Crizotinib or ceritinib</td>
<td>Erlotinib</td>
</tr>
<tr>
<td>3</td>
<td>TKI if not used</td>
<td>Crizotinib or ceritinib</td>
<td>Erlotinib</td>
</tr>
<tr>
<td>4</td>
<td>TKI if not used</td>
<td>Crizotinib or ceritinib</td>
<td>Erlotinib</td>
</tr>
<tr>
<td><strong>Third Line</strong></td>
<td>IT, if not used TKI</td>
<td>IT, Crizotinib, ceritinib or erlotinib, if both ceritinib and crizotinib used</td>
<td>IT, if not used Erlotinib</td>
</tr>
<tr>
<td>0-3</td>
<td>IT, if not used TKI</td>
<td>IT, Crizotinib, ceritinib or erlotinib, if both ceritinib and crizotinib used</td>
<td>IT, if not used Erlotinib</td>
</tr>
<tr>
<td>4</td>
<td>Palliative Care</td>
<td>Palliative Care</td>
<td>Palliative Care</td>
</tr>
</tbody>
</table>

CM = Continuation Maintenance  TKI = Tyrosine Kinase Inhibitors: Erlotinib, Afatinib and Gefitinib. IT: Nivolumab and Pembrolizumab

CONTACT

P. O. Box 106911
Riyadh 11676, Saudi Arabia
Tel. #: +966 11 2488966
Fax #: +966 11 2487431
Email: saudithoracicsociety@yahoo.com

© Saudi Thoracic Society 2015, All Rights Reserved